RT info:eu-repo/semantics/article
T1 Daily headache in chronic migraine Is a predictive factor of response in patients who had completed three sessions of OnabotulinumtoxinA
A1 Martínez Pías, Enrique
A1 Guerrero Peral, Angel Luis
A1 Sierra, Álvaro
A1 Trigo, Javier
A1 García Azorín, David
K1 Neurology
K1 Internal Medicine
K1 Botulinum toxin type A
K1 Headache disorders
K1 Migraine
K1 Toxina botulínica tipo A
K1 Trastornos de cefalea
K1 Migraña
K1 32 Ciencias Médicas
K1 3205.07 Neurología
AB OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to one third of patients with chronic migraine suffer from daily headache, these individuals have hardly been studied. We conducted a prospective cohort study, including patients with chronic migraine and treated with OnabotulinumtoxinA according to the PREEMPT paradigm. The primary endpoint was to assess whether patients with chronic migraine and daily headache had a different response after three sessions of OnabotulinutoxinA than patients without daily headache. The secondary endpoint was to analyse the presence of predictive factors that could be associated with a higher response to OnabotulinumtoxinA. Patients with daily headache had a reduction of 14.9 (SD: 9.7) headache days per month, patients with 22–29 headache days a reduction of 10.6 (SD: 9.9) days, and patients with 15–21 headache days a reduction of 8.6 (SD: 7.1) days (p < 0.001). In the univariate regression analysis, a higher number of headache days per month at baseline was associated with higher odds of reduction in the number of headache days per month after OnabotulinumtoxinaA treatment (OR: 0.474, 95% CI: 0.278–0.670, p < 0.001). This association was maintained in the multivariate regression analysis (OR: 0.540, 95% CI: 0.333–0.746, p < 0.001). In our sample, daily headache was not associated with a worse response to OnabotulinumtoxinA treatment. A higher frequency of headache at baseline was a predictor of better response to OnabotulinumtoxinA treatment.
PB MDPI
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59548
UL https://uvadoc.uva.es/handle/10324/59548
LA eng
NO Toxins, 2021, vol. 13, n. 6, 432
NO Producción Científica
DS UVaDOC
RD 17-jul-2024